Table 1.
Baseline characteristics of subjects initiated with alendronate and denosumab after diabetes diagnosis in Denmark from 2011 to 2018.
| All subjects n = 8,745 | Alendronate n = 8,255 | Denosumab n = 490 | |
|---|---|---|---|
| Age (years), mean ± SD | 73.62 (9.27) | 73.51 (9.23) | 75.60 (9.72) |
| Age category (years), n (%) | |||
| 50–59 | 755 (9) | 720 (9) | 35 (7) |
| 60–69 | 2,196 (25) | 2,100 (25) | 96 (20) |
| 70–79 | 3,481 (40) | 3,293 (40) | 188 (38) |
| ≥80 | 2,313 (26) | 2,142 (26) | 171 (35) |
| Sex, n (%) | |||
| Female | 6,043 (69) | 5,647 (68) | 396 (81) |
| Male | 2,702 (31) | 2,608 (32) | 94 (19) |
| Type 2 diabetes, n (%) | 8,589 (98) | 8,114 (98) | 475 (97) |
| Diabetes duration in years, median (IQR) | 5.45 (2.41-9.19) | 5.43 (2.41-9.18) | 5.57 (2.34-9.52) |
| History of any fracture, n (%) | 4,141 (47) | 3,828 (46) | 313 (64) |
| CCI, mean ± SD | 1.81 (1.89) | 1.78 (1.88) | 2.26 (2.07) |
| CCI categories, n (%) | |||
| 0 | 2,609 (30) | 2,491 (30) | 118 (24) |
| 1 | 1,963 (22) | 1,879 (23) | 84 (17) |
| ≥2 | 4,173 (48) | 3,885 (47) | 288 (59) |
| Peptic ulcer, n (%) | 507 (6) | 455 (6) | 52 (11) |
| Renal impairment, n (%) | 693 (8) | 615 (7) | 78 (16) |
| Income, € in thousands, median (IQR) | 26.13 (19.85-32.54) | 26.11 (19.85-32.58) | 26.44 (19.92-31.53) |
| 1st quintile, n (%) | 1,749 (20) | 1,645 (20) | 104 (21) |
| 2nd quintile, n (%) | 1,749 (20) | 1,677 (20) | 72 (15) |
| 3rd quintile, n (%) | 1,749 (20) | 1,637 (20) | 112 (23) |
| 4th quintile, n (%) | 1,749 (20) | 1,637 (20) | 112 (23) |
| 5th quintile, n (%) | 1,749 (20) | 1,659 (20) | 90 (18) |
| Marital status, n (%) | |||
| Married | 4,241 (49) | 4,015 (49) | 226 (56) |
| Divorced | 1,358 (16) | 1,280 (16) | 78 (16) |
| Unmarried | 606 (6.93) | 574 (7) | 32 (7) |
| Widowed | 2,534 (29) | 2,380 (29) | 154 (31) |
| Unknown | 6 (0) | 6 (0) | 0 (0) |
| Heavy smoking, n (%) | 3,116 (36) | 2,927 (35) | 189 (39) |
| Alcohol abuse, n (%) | 747 (9) | 708 (9) | 39 (8) |
| Obesity, n (%) | 1,543 (18) | 1,457 (18) | 86 (18) |
| Pancreatitis, n (%) | 298 (3) | 283 (3) | 15 (3) |
| Hyperthyroidism, n (%) | 279 (3) | 254 (3) | 25 (5) |
| Hypothyroidism, n (%) | 629 (7) | 589 (7) | 40 (8) |
| Glucocorticoid use, n (%) | 5,027 (57) | 4,757 (58) | 270 (55) |
| Statin use, n (%) | 6,791 (78) | 6,424 (78) | 367 (75) |
| Insulin use, n (%) | 1,654 (19) | 1,543 (19) | 111 (23) |
| Hypoglycemia, % ± SD | 193 (2) | 177 (2) | 16 (3) |
| Hypertension, n (%) | 7,996 (91) | 7,543 (91) | 453 (92) |
| Opioid use, n (%) | 6,755 (77) | 6,342 (77) | 413 (84) |
| Anxiolytics, n (%) | 7,741 (89) | 7,286 (88) | 455 (93) |
| Initiation year, n (%) | |||
| 2011 | 1,098 (13) | 1,018 (12) | 80 (16) |
| 2012 | 1,052 (12) | 989 (12) | 63 (13) |
| 2013 | 1,076 (12) | 1,018 (12) | 58 (12) |
| 2014 | 1,100 (13) | 1,044 (13) | 56 (11) |
| 2015 | 1,072 (13) | 1,021 (12) | 51 (10) |
| 2016 | 1,113 (13) | 1,050 (13) | 63 (13) |
| 2017 | 1,155 (13) | 1,099 (13) | 56 (11) |
| 2018 | 1,079 (12) | 1,016 (12) | 63 (13) |
All characteristics were evaluated in the time from 2000 until the index date (exposure start). Data are presented as numbers (n, %), mean with SD or median with IQR.